AFFILIATION AGREEMENTAffiliation Agreement • March 9th, 2007 • Tercica Inc • Pharmaceutical preparations • New York
THIS AFFILIATION AGREEMENT (this Agreement) is made effective as of the Effective Date, by and between: (1) TERCICA, INC., a Delaware corporation with its principal office at 2000 Sierra Point Parkway, Suite 400, Brisbane, California 94005, USA (the Company); (2) SURAYPHARM, a Société par Actions Simplifiée organized under the laws of France with its registered address at 42, rue du Docteur Blanche, 75016 Paris, France (the Investor), which is an assignee of Ipsen (as defined below) under the Purchase Agreement (as defined below) and the purchaser of the Shares (as defined therein); and, solely for purposes of Sections 2.7, 2.9, 2.10, 7 and 8 hereof, (3) IPSEN, S.A., a société anonyme organized under the laws of France with its registered address at 42, rue du Docteur Blanche, 75016 Paris, France (Ipsen).
INCRELEX™ LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • March 9th, 2007 • Tercica Inc • Pharmaceutical preparations
THIS INCRELEX™ LICENSE AND COLLABORATION AGREEMENT (the “Agreement”), is entered into as of the Effective Date (defined below) by and between Tercica, Inc., a company incorporated under the laws of Delaware with offices at 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005, United States of America (“Licensor”) and Beaufour Ipsen Pharma, a company incorporated under the laws of France with offices at 24 rue Erlanger, 75016 Paris, France (“Licensee”). Licensor and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
TERCICA, INC. CONSENT, WAIVER AND AMENDMENTConsent, Waiver and Amendment • March 9th, 2007 • Tercica Inc • Pharmaceutical preparations • California
THIS CONSENT, WAIVER AND AMENDMENT (the “Agreement”) is made effective as of the Effective Date by and among TERCICA, INC., a Delaware corporation (the “Company”), the undersigned Founders (the “Consenting Founders”) and the undersigned Investors (the “Consenting Investors”).
SOMATULINE® LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • March 9th, 2007 • Tercica Inc • Pharmaceutical preparations
THIS SOMATULINE® LICENSE AND COLLABORATION AGREEMENT (the “Agreement”), is entered into as of the Effective Date (defined below) by and between SCRAS, a company incorporated under the laws of France with offices at 42 rue du Docteur Blanche, 75016 Paris, France (“SCRAS”) and Beaufour Ipsen Pharma, a company incorporated under the laws of France with offices at 24 rue Erlanger, 75016 Paris, France (“BIP”) (SCRAS and BIP acting jointly being together referred to as “Licensors”), and Tercica, Inc. a company incorporated under the laws of Delaware with offices at 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005, United States of America (“Licensee”). BIP, SCRAS, either individually or acting jointly as Licensors on the one hand, and Licensee, on the other hand, are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
